Wearable Health Solutions (WHSI) 10-K/A 1 May 15 2014 FY Annual report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Oct. 27, 2014
Document And Entity Information
Entity Registrant Name	MEDICAL ALARM CONCEPTS HOLDINGS INC
Entity Central Index Key	1443089
Document Type	10-K
Document Period End Date	30-Jun-14
Amendment Flag	TRUE
Amendment Description	This Second Amendment to Form 10-K (the “Form 10-K/A-2”) is being filed by Medical Alarm Concepts Holdings, Inc. (the “Company”) in response to comments made by the staff of the Securities and Exchange Commission (“SEC”) by letter dated April 20, 2015 on the presentation in the Company in its original annual report on Form 10-K for the fiscal year ended June 30, 2014 filed with the SEC on November 3, 2014, and as subsequently amended on April 10, 2015. Except as necessary to respond to the SEC staff comments, the Company has not modified or updated disclosures presented in the original annual report on Form 10-K, as subsequently amended on April 10, 2015. Accordingly, this Form 10-K/A-2 does not reflect events occurring after the filing of our original Form 10-K or modify or update those disclosures affected by subsequent events, except as specifically referenced herein. Accordingly, this Form 10-K/A-2 should be read in conjunction with our periodic filings made with the SEC subsequent to the date of the original filing, including any amendments to those filings, as well as any Current Reports filed on Form 8-K subsequent to the date of the original filing.
Current Fiscal Year End Date	-24
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$0
Entity Common Stock, Shares Outstanding		5,628,679
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Jun. 30, 2013
CURRENT ASSETS
Cash	$7,673	$5,857
Accounts receivable net of allowance of $7,906 and $nil	36,952	11,607
Inventory	22,839	26,136
Prepaid expense		32,661
Total current assets	67,464	76,261
NON-CURRENT ASSETS
Property and equipment, net	461	5,714
Intangible assets, net	1,099,036	1,177,538
Total non-current assets	1,099,497	1,183,252
Total assets	1,166,961	1,259,513
CURRENT LIABILITIES
Derivative liability	30,766	2,455,628
Accounts payable	67,305	71,623
Deferred revenue	380,397	275,191
Note payable - related party		29,000
Note payable - other	5,000
Accrued expenses and other current liabilities	194,025	367,798
Convertible notes payable - current	25,908	54,330
Total current liabilities	703,401	3,253,570
NON-CURRENT LIABILITIES
Credit line payable - related party		618,844
Patent payable	2,500,000	2,500,000
Convertible notes payable, net of discount		225,165
Total non-current liabilities	2,500,000	3,344,009
Total liabilities	3,203,401	6,597,579
STOCKHOLDERS' DEFICIT
Common stock: $0.0001 par value; 20,000,000 shares authorized; 5,623,679 and 1,696,813 shares issued and outstanding on June 30, 2014 and 2013, respectively	562	170
Additional paid-in capital	12,203,981	9,127,788
Accumulated deficit	-14,240,984	-14,466,025
Total stockholders' deficit	-2,036,440	-5,338,066
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,166,961	1,259,513
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Series A Convertible Preferred Stock: $0.0001 par value; 100,000 shares authorized; 688 shares issued and outstanding as of June 30, 2014 and 2013, respectively Series B Convertible Preferred Stock: $0.0001 par value; 62,500 shares authorized; 9,938 shares issued and outstanding as of June 30, 2014 and 2013, respectively
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Series A Convertible Preferred Stock: $0.0001 par value; 100,000 shares authorized; 688 shares issued and outstanding as of June 30, 2014 and 2013, respectively Series B Convertible Preferred Stock: $0.0001 par value; 62,500 shares authorized; 9,938 shares issued and outstanding as of June 30, 2014 and 2013, respectively	$1	$1

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Accounts receivable net	$7,906
Common stock par value	$0.00	$0.00
Common stock shares authorized	20,000,000	20,000,000
Common stock shares issued	5,623,679	1,696,813
Common stock shares outstanding	5,623,679	1,696,813
Series A Preferred Stock [Member]
Convertible Preferred Stock par value	$0.00	$0.00
Convertible Preferred Stock shares authorized	100,000	100,000
Convertible Preferred Stock shares issued	688	688
Convertible Preferred Stock shares outstanding	688	688
Series B Preferred Stock [Member]
Convertible Preferred Stock par value	$0.00	$0.00
Convertible Preferred Stock shares authorized	62,500	62,500
Convertible Preferred Stock shares issued	9,938	9,938
Convertible Preferred Stock shares outstanding	9,938	9,938

STATEMENTS_OF_COMPREHENSIVE_IN

STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]
Revenue	$1,153,693	$572,712
Cost of revenue	324,503	441,788
Gross profit	829,190	130,924
Operating expenses
Selling expense	212,133	244,162
General and administrative	1,695,423	628,273
Total operating expenses	1,907,556	872,435
Loss from operations	-1,078,366	-741,511
Other (income) expenses
Change in fair value of derivative instrument	-1,514,947	-4,500,057
Interest expense	211,540	569,460
Total other (income) expense	-1,303,407	-3,930,597
Income before income tax	225,041	3,189,086
Income tax provision
Net income	$225,041	$3,189,086
Net income per common share - basic and diluted	$0.06	$3.47
Weighted average number of common shares - basic and diluted	3,787,467	918,391

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (USD $)	Series A Preferred Stock	Series B Preferred Stock	Common Stock	Additional Paid-In Capital	Deficit Accumulated	Total
		USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Beginning balance, Amount at Jun. 30, 2012		$1	$72	$7,407,291	($17,655,111)	($10,247,747)
Beginning balance, Shares at Jun. 30, 2012	688	9,938	717,103
Conversion of convertible notes to Common Stock, Amount			35	994,054		994,089
Conversion of convertible notes to Common Stock, Shares			354,893
Issuance of common stocks for cash, Amount			63	291,688		291,751
Issuance of common stocks for cash, Shares			623,468
Share-based compensation				28,267		28,267
Forgiveness of warrants				403,417		403,417
Stock issued for cashless exercise of warrants, Amount				3,071		3,071
Stock issued for cashless exercise of warrants, Shares			1,349
Issuance of common stocks for services Amount						28,267
Stock issued for payment of interest, Amount					3,189,086	3,189,086
Ending balance, Amount at Jun. 30, 2013		1	170	9,127,788	-14,466,025	-5,338,066
Ending balance, Shares at Jun. 30, 2013	688	9,938	1,696,813
Conversion of convertible notes to Common Stock, Amount			216	343,603		343,819
Conversion of convertible notes to Common Stock, Shares			2,160,180
Issuance of common stocks for cash, Amount			12	76,888		76,900
Issuance of common stocks for cash, Shares			123,014
Issuance of common stocks for services Amount			154	994,294		994,448
Issuance of common stocks for services, Shares			1,543,669
Forgiveness of credit line				618,844		618,844
Derivative liability classified to additional paid-in capital upon conversion of related convertible notes				909,918		909,915
Accrued interest and debt discount classified to additional paid-in capital upon conversion and forgiveness of debt				107,656		107,656
Stock issued for payment of interest, Amount			10	24,990
Stock issued for payment of interest, shares			100,000
Net loss					225,041	225,041
Ending balance, Amount at Jun. 30, 2014		$1	$562	$12,203,981	($14,240,984)	($2,036,440)
Ending balance, Shares at Jun. 30, 2014	688	9,938	5,623,676

STATEMENTS_OF_CASH_FLOWS_Unaud

STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Statement of Cash Flows [Abstract]
Net income (loss)	$225,041	$3,189,086
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services	994,448	28,267
Common stock issued for interest	25,000	0
Change in fair value of derivative instrument	-1,514,947	-4,500,057
Amortization of patent	78,503	78,503
Non-cash interest expense	28,991	337,857
Depreciation	5,253	5,250
Bad debt expense	7,906
Change in operating assets and liabilities
Accounts receivable	-33,249	-10,792
Inventory	3,297	25,906
Prepaid expenses	32,661	-32,661
Accounts payable	-4,318	-16,912
Accrued expenses and other current liabilities	20,524	191,389
Deferred revenue	105,206	207,044
Net Cash Used in Operating Activities	-25,684	-497,120
CASH FLOWS FROM FINANCING ACTIVITIES
Cash received from loan receivable		60,000
Proceeds from convertible notes		58,000
Proceeds from note payable - other	5,000
Proceeds from issuance of common stock, net of costs	22,500	346,150
Repayment of credit line - related party		-10,750
Proceeds from (repayment of) loan payable - related party		29,000
Net Cash Provided By Financing Activities	27,500	482,400
NET INCREASE (DECREASE) IN CASH	1,816	-14,720
CASH AT BEGINNING OF PERIOD	5,857	20,577
CASH AT END OF PERIOD	7,673	5,857
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest expense	125,000	150,090
Cash paid for income taxes
Conversion of convertible notes to common stock	314,819	64,883
Derivative liability classified to additional paid-in capital upon forgiveness of warrants		403,417
Derivative liability classified to additional paid-in capital upon conversion of related convertible notes	909,915	929,206
Debt discount from derivative liability		58,000
Issuance of common stock previously classified as stock to be issued	54,400
Forgiveness of credit line payable classified to additional paid-in capital	618,843
Accrued interest and debt discount classified to additional paid-in capital upon conversion and forgiveness of debt	$107,656

NATURE_OF_OPERATIONS

NATURE OF OPERATIONS	12 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1   NATURE OF OPERATIONS
	On June 4, 2008, Medical Alarm Concepts Holding, Inc. (the “Company”) was incorporated under the laws of the State of Nevada. The Company was formed for the sole purpose of acquiring all of the membership units of Medical Alarm Concepts LLC, a Pennsylvania limited liability company (“Medical LLC”).
	On June 24, 2008, the Company merged with Medical LLC. The members of Medical LLC received 30,000,000 shares of the Company’s common stock, or 100 % of the outstanding shares in the merger. As of the date of the merger, Medical LLC was inactive.
	The Company utilizes new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical or age-related conditions.

SUMMARY_OF_ACCOUNTING_POLICIES

SUMMARY OF ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]
SUMMARY OF ACCOUNTING POLICIES	NOTE 2   SUMMARY OF ACCOUNTING POLICIES
	Basis of Presentation and Consolidation
	The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”).
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant inter-company transactions and balances among the Company and its subsidiary are eliminated upon consolidation.
	Certain amounts included in June 30, 2013 financial statements have been reclassified to conform to the June 30, 2014 financial statements presentation.
	Reverse Split
	On February 14, 2014, the company filed a Certificate of Change with the State of Nevada to effect a 1-for-800 reverse stock split on the issued and outstanding preferred and common stock. All relevant information relating to numbers of shares, warrants and per share information have been retrospectively adjusted to reflect the reverse stock split for all periods presented.
	Use of Estimates
	The preparation of the financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include the collectability of accounts receivable, deferred taxes and related valuation allowances and value of derivative financial instruments. Certain of our estimates, including evaluating the collectability of accounts receivable, could be affected by external conditions, including those unique to our industry, and general economic conditions. It is possible that these external factors could have an effect on our estimates that could cause actual results to differ from our estimates. We re-evaluate all of our accounting estimates at least quarterly based on these conditions and record adjustments when necessary.
	Cash
	The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash and cash equivalents.
	Accounts receivable and allowance for doubtful accounts receivable
	We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. We extend credit to our customers based on an evaluation of their financial condition and other factors. We generally do not require collateral or other security to support accounts receivable. We perform ongoing credit evaluations of our customers and maintain an allowance for potential bad debts if required.  We determine whether an allowance for doubtful accounts is required by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. In these cases, we use assumptions and judgment, based on the best available facts and circumstances, to record a specific allowance for those customers against amounts due to reduce the receivable to the amount expected to be collected. These specific allowances are re-evaluated and adjusted as additional information is received. The amounts calculated are analyzed to determine the total amount of the allowance. We may also record a general allowance as necessary.  Direct write-offs are taken in the period when we have exhausted our efforts to collect overdue and unpaid receivables or otherwise evaluate other circumstances that indicate that we should abandon such efforts.
	Inventory
	The Company values inventory, consisting of purchased products, at the lower of cost or market. Cost is determined on the first-in and first-out (“FIFO”) method. The Company regularly reviews its inventories on hand and, when necessary, records a provision for excess or obsolete inventories based primarily on current selling price and spot market prices. The Company determined that there was no inventory obsolescence as of June 30, 2014 and 2013.
	Property and equipment
	Property and equipment includes furniture and fixtures and office equipment which are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of furniture and fixtures and office equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over their estimated useful life of seven (7) and five (5) years, respectively. Upon sale or retirement of office equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in statements of operations.
	Patent
	The Company has adopted the guidelines as set out in section 330-30-35-6 of the FASB Accounting Standards Codification (“ASC”) for patent costs. Under the requirements as set out, the Company capitalizes and amortizes patent costs associated with the licensed product the Company intends to sell pursuant to the Purchase Agreement and the Patent Assignment Agreements, entered into on July 10, 2008 and effective July 30, 2008, over their estimated useful life. From July 30, 2008 to March 31, 2011, the patent cost was amortized over the period of six years. The company changed the estimated useful life of patent from six years to twenty years. From April 1, 2011, the unamortized balance of patent costs will be amortized over the remaining period of useful life. The costs of defending and maintaining patents are expensed as incurred. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
	Impairment of long-lived assets
	The Company follows section 360-10-05-4 of the FASB ASC for its long-lived assets. The Company’s reviews it long-lived assets, which include property and equipment, and patent, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
	The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future undiscounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated or amortized over the newly determined remaining estimated useful lives. The Company determined that there were no impairments of long-lived assets as of June 30, 2014 and 2013.
	Convertible instruments and derivative financial instruments
	The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with paragraph 810-10-05-4 of the FASB ASC and paragraph 815-40-25 of the FASB ASC. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the Statement of Operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.
	In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.
	On January 1, 2009, the Company adopted Section 815-40-15 of the FASB ASC (“Section 815-40-15”) to determine whether an instrument (or an embedded feature) is indexed to the Company’s own stock. Section 815-40-15 provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The adoption of Section 815-40-15 has affected the accounting for (i) certain freestanding warrants that contain exercise price adjustment features and (ii) convertible bonds issued by foreign subsidiaries with a strike price denominated in a foreign currency.
	Fair Value of Financial Instruments
	The Company follows paragraph 825-10-50-10 of the FASB ASC for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value pursuant to GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:
	Level 1   Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
	Level 2   Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
	Level 3   Pricing inputs that are generally observable inputs and not corroborated by market data.
	The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, inventory, prepaid expenses, accounts payable, deferred revenues and accrued liabilities, approximate their fair values because of the short maturity of these instruments. The Company’s convertible notes payable approximate the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at June 30, 2014 and 2013.
	The derivative liability which consists of embedded conversion feature and warrants issued in connection with our convertible debt, classified as a level 3 liability, are the only financial liability measured at fair value on a recurring basis. (See Note 10)
	Income Taxes
	The Company accounts for income taxes under the provisions of FASB ASC Topic 740, “Income Tax,” which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are recognized for the future tax consequence attributable to the difference between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are measured using the enacted tax rate expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company establishes a valuation when it is more likely than not that the assets will not be recovered.
	ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for any of the reporting periods presented.
	Revenue Recognition
	The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical or age-related conditions. The Company applies paragraph 605-10-S99-1 of the FASB ASC for revenue recognition. The Company will recognize revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement that the services have been rendered to the customer, the sales price is fixed or determinable, and collectability is reasonably assured.
	All revenues from subscription arrangements are recognized ratably over the term of such arrangements. The excess of amounts received over the income recognized is recorded as deferred revenue on the consolidated balance sheet.
	Shipping and handling costs
	The Company accounts for shipping and handling fees in accordance with paragraph 605-45-45-19 of the FASB ASC. While amounts charged to customers for shipping products are included in revenues, the related costs are classified in cost of goods sold as incurred.
	Stock-based compensation
	We recognize compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, we calculate the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for unrestricted shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, we calculate the fair value of the award on the date of grant in the same manner as employee awards. However, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.
	The Black-Scholes option valuation model is used to estimate the fair value of the warrants or options granted. The model includes subjective input assumptions that can materially affect the fair value estimates. The model was developed for use in estimating the fair value of traded options or warrants. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the warrants or options granted.
	Net loss per common share
	Net loss per common share is computed pursuant to section 260-10-45 of the FASB ASC. Basic net loss per common share is computed by taking net loss divided by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debt. These potential shares of common stock were not included as they were anti-dilutive.
	Commitments and contingencies
	The Company follows subtopic 450-20 of the FASB ASC to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
	Cash flows reporting
	The Company adopted paragraph 230-10-45-24 of the FASB ASC for cash flows reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by paragraph 230-10-45-25 of the FASB ASC to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The Company reports the reporting currency equivalent of foreign currency cash flows, using the current exchange rate at the time of the cash flows and the effect of exchange rate changes on cash held in foreign currencies is reported as a separate item in the reconciliation of beginning and ending balances of cash and cash equivalents and separately provides information about investing and financing activities not resulting in cash receipts or payments in the period pursuant to paragraph 830-230-45-1 of the FASB Accounting Standards Codification.
	Subsequent events
	The Company follows the guidance in Section 855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company evaluates subsequent events through the date when the financial statements are issued. Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR.
	Recently Accounting Pronouncements
	In April 2014, the FASB issued amendments to ASC Topic 205 “Presentation of Financial Statements” and ASC Topic 360 “Property, Plant and Equipment”. The amendments change the current requirements for reporting discontinued operations in Subtopic 205-20. It requires an entity to present, for each comparative period, the assets and liabilities of a disposal group that includes a discontinued operation separately in the asset and liability section, respectively, of the statement of financial position. This topic is effective for public entities for reporting periods beginning after December 15, 2014. An entity should not apply the amendments to a component classified as held for sale before the effective date even if the component of an entity is disposed of after the effective date. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued. The Company does not believe the adoption of the amendments to ASC 205 and ASC 360 will have a material effect on its consolidated financial statements.
	Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

GOING_CONCERN

GOING CONCERN	12 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3   GOING CONCERN
	These consolidated financial statements are presented on the basis that we will continue as a going concern. The going concern concept contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
	As the accompanying consolidated financial statements, the Company has working capital deficit of $635,937, did not generate cash from its operations, had stockholders’ deficit of $2,036,440 and had operating losses for past two years. These circumstances, among others, raise substantial doubt about the Company’s ability to continue as a going concern.
	While the Company is attempting to generate sufficient revenues, the Company’s cash position may not be enough to support the Company’s daily operations. Management intends to raise additional funds by way of a public or private offering. Management believes that the actions presently being taken to further implement its business plan and generate sufficient revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to increase revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenues.
	The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Jun. 30, 2014
Notes to Financial Statements
INTANGIBLE ASSETS	NOTE 4 – INTANGIBLE ASSETS
	On July 10, 2008, the Company entered into a Purchase Agreement and Patent Assignment Agreement (the “Agreement”) to be effective July 31, 2008. The Company was obligated to pay the seller $2,500,000 on June 30, 2012. The Agreement specifies interest of 6% to be payable monthly, commencing on July 31, 2008. The seller will reacquire all patents and applications if payment was not made on June 30, 2012. On September 30, 2014, this due date was extended to December 31, 2014.
	Amortization of patent aggregated $78,503 for the year ended June 30, 2014 and 2013 respectively.
	Patent, stated at cost, less accumulated amortization consisted of the following:
		June 30, 2014			June 30, 2013
	Patent	$	2,500,000		$	2,500,000
	Less: accumulated amortization		(1,400,964	)		(1,322,462	)
		$	1,099,036		$	1,177,538

ACCRUED_EXPENSES_AND_OTHER_CUR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	12 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
	The following table presents accrued expenses and other current liabilities.
		30-Jun-14		30-Jun-13
	Accrued expenses	$	194,025	$	169,952
	Accrued interest		—		107,988
	Stock to be issued		—		54,400
	Advance from customer		—		35,458
	Total	$	194,025	$	367,798

CREDIT_LINE_RELATED_PARTY

CREDIT LINE - RELATED PARTY	12 Months Ended
	Jun. 30, 2014
Credit Line Related Party
CREDIT LINE - RELATED PARTY	NOTE 6 - CREDIT LINE – RELATED PARTY
	On January 6, 2012, the Company and Biotech Development Group, LLC. (“Biotech”), a shareholder, entered into a credit line agreement (“Credit Line Agreement”), pursuant to which, Biotech agreed to give the Company a line of credit to borrow up to $500,000. The principal balance is due on December 31, 2012. This credit line bears interest at 8% per annum and due quarterly. On May 18, 2012, the credit line was increased to $750,000. On June 11, 2013, the due date of the credit line was extended to December 31, 2014. On December 10, 2013, the balance of credit line was forgiven. Since the credit line is from a related party, the amount forgiven was recorded in additional paid-in capital. See Note 7 Stockholders’ Equity.

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	12 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 7 - CONVERTIBLE NOTES PAYABLE
	The convertible notes are convertible into shares of the Company’s common stock at a fixed conversion price equal to the lesser of the fixed conversion price of $0.002, or seventy five percent (75%) of the average of the closing bid price of the common stock as reported by Bloomberg LP for the principal market for the 5 trading days preceding the conversion date. The convertible notes balance as of June 30, 2014 was $25,908 and was due on March 31, 2013.
	During the year ended June 30, 2013, the Company issued convertible notes of $58,000. The convertible notes are convertible into shares of the Company’s common stock at a fixed conversion price equal to the lesser of the fixed conversion price of $0.0014, or seventy five percent (75%) of the average of the closing bid price of the common stock as reported by Bloomberg LP for the principal market for the 5 trading days preceding the conversion date and due in November 15, 2014. As part of this transaction, the Company also issued warrants to purchase 51,250 shares of common stock. The exercise price is $0.0014 per share.
	During the year ended June 30, 2013, convertible notes with total face amount of $64,883 were converted to 354,893 shares of common stock.
	During the year ended June 30, 2014, convertible notes with total face amount of $314,819 were converted pursuant to Global Settlement Agreement. (See Note 8 – Stockholder’s Equity)
	The following table summarizes the convertible promissory notes movement of fiscal 2014 and 2013:
	Balance at June 30, 2012	$	347,610
	Convertible notes issued		58,000
	Convertible notes converted		(64,883	)
	Total		340,727
	Less: debt discount		(61,232	)
	Balance at June 30, 2013		279,495
	Less: current portion		(54,330	)
	Long-term portion		225,165
	Balance at June 30, 2013		340,727
	Convertible notes issued		—
	Convertible notes converted		(314,819	)
	Total		25,908
	Less: debt discount		—
	Balance at June 30, 2014		25,908

STOCKHOLDERS_EQUITY

STOCKHOLDERS EQUITY	12 Months Ended
	Jun. 30, 2014
Equity [Abstract]
STOCKHOLDERS EQUITY	NOTE 8 – STOCKHOLDERS’ EQUITY
	During fiscal year ended June 30, 2013, the Company issued 623,468 shares of common stocks for cash of $291,751.
	During fiscal year ended June 30, 2013, the Company issued 1,349 shares of common stocks as a result of cashless exercise of warrants.
	During the fiscal year ended June 30, 2014, 123,014 shares of common stocks were issued to investors for $76,900 cash. $54,400 was received during the year ended June 30, 2013 and was classified as the liability for common stock to be issued, which was included in accrued expense and other current liabilities at June 30, 2013 and reclassified to equity upon issuance of the shares.
	On December 10, 2013, the Company entered into a Global Settlement Agreement (the “Agreement”). Pursuant to the term of a Global Settlement Agreement (“GSA”) among the Company, Biotech and the management team, as defined:
		1	Biotech forgave any outstanding borrowings of the Company under the Credit Line referred to in Note 6 for no consideration.
		2	Outstanding convertible notes aggregating $314,819 were converted into 2,123,930 shares of the Company’s common stock.
		3	The management team agreed to forfeit its rights to future anti-dilution of its ownership position in exchange for 1,493,669 shares of the Company’s common stock. The shares issued were valued at $0.64 per share which is the market price in December 10, 2013 and recorded as stock compensation expense.
	Both parties also agreed on the following terms: 1) the management team agreed to modify its September 19, 2011 agreement with the Company giving up all anti-dilution rights, 2) the Company agreed to take steps to increase the number of authorized shares to accommodate the debt conversions and would complete a reverse split of its shares, 3) The Company would file a registration statement with the SEC, and 4) the Company would continue to file past due periodic reports with the SEC on Forms 10-Q and 10-K in order to return the Company to full reporting status, a process that is already well underway.
	On February 5, 2014 the Company issued 50,000 shares of common stock to a shareholder as compensation for consulting services provided to the Company. Those shares were valued at the quoted market price for total $38,500 and recorded as expense.
	On February 5, 2014, the Company issued 36,250 shares of common stock to a related note holder as repayment of promissory note of $29,000. See Note 10.
	On June 26, 2014, the Company issued 100,000 shares of common stock to a note holder for payment of interest (See Note 4)

WARRANTS

WARRANTS	12 Months Ended
	Jun. 30, 2014
Notes to Financial Statements
WARRANTS	NOTE 9 - WARRANTS
	During the year ended June 30, 2013, investors agreed to forgive warrants to purchase 224,378 shares of common stock. Fair market value of warrants forgiven classified as derivative liability totaled $403,417 was recorded as additional paid-in capital.
	On March 4, 2013, two investors exercised warrants to purchase 1,477 shares of common stocks on cashless basis. Resulting from their conversion, the Company issued 1,349 shares of common stocks to them.
	The following table summarizes the movement of warrants:
		Number of shares
		Prior to Reverse Stock Split	After Reverse Stock Split	Weighted average exercise price
	Outstanding at June 30, 2012	139,683,763	174,605	0.0002
	Granted	41,000,000	51,250	0.0014
	Exercised	-1,181,707	-1,477	0.0002
	Forgiven	-179,502,056	-224,378	0.0002
	Outstanding at June 30, 2013	-	-	-

DERIVATIVE_WARRANT_LIABILITY_A

DERIVATIVE WARRANT LIABILITY AND FAIR VALUE	12 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]
DERIVATIVE WARRANT LIABILITY AND FAIR VALUE	NOTE 10 - DERIVATIVE LIABILITY AND FAIR VALUE
	The Company has evaluated the application of ASC 815 Derivatives and Hedging (formerly SFAS No. 133) and ASC 815-40-25 to the Warrants to purchase common stock issued with the Convertible Notes and service agreements. Based on the guidance in ASC 815 and ASC 815-40-25, the Company concluded these instruments were required to be accounted for as derivatives due to the down round protection feature on the conversion price and the exercise price. The Company records the fair value of these derivatives on its balance sheet at fair value with changes in the values of these derivatives reflected in the statements of operations as “Gain (loss) on derivative liabilities.” These derivative instruments are not designated as hedging instruments under ASC 815 and are disclosed on the balance sheet under Derivative Liabilities.
	The Company accounted for the issuance of the convertible debentures in accordance with ASC 815” Derivatives and Hedging.” The debentures are convertible into an indeterminate number of shares for which the Company cannot determine if it has sufficient authorized shares to settle the transaction with.  Accordingly, the embedded conversion option is a derivative liability and is marked to market through earnings at the end of each reporting period.
	The gross proceed from the sale of the debentures are recorded net of a discount of related to the conversion feature of the embedded conversion option.  When the fair value of conversion options is in excess of the debt discount the amount has been included as a component of interest expense in the statement of operations. During the year ended June 30, 2013, the Company recorded $261,230 of interest expense relating to the excess fair value of the conversion option over the face value of the debentures.
	The fair value of the Warrants underlying the promissory notes issued at the time of their issuance was calculated pursuant to the Black-Scholes option pricing model. The fair value was recorded as a reduction to the promissory notes payable and was charged to operations as interest expense in accordance with effective interest method within the period of the promissory notes. Significant assumptions used in calculating fair value of outstanding warrants are as follows.
						Risk-free
	Expected			Expected		rate of	Expected term	Exercise		Underlying
	dividend			volatility		Interest	(year)	Price		Number of shares
		—			193.89% - 322.21%	0.07 %/ 1 year	As set forth by each promissory note agreement	$	0.0002	As set forth by each promissory note agreement
						0.35 %/ 2 years
						0.5 %/ 3 years
	The following table provides a summary of the changes in fair value of derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs during the year ended June 30, 2014 and 2013.
	Balance - July 1, 2012		8,043,577
	Issuances during the year		261,230
	Conversion and forgivenss during the year		(1,349,122	)
	changes in fair value included in earnings		(4,500,057	)
	Balance - June 30, 2013		2,455,628
	Issuances during the year		—
	Conversion during the year		(909,915	)
	changes in fair value included in earnings		(1,514,947	)
	Balance - June 30, 2014		30,766

NOTE_PAYABLE_OTHER

NOTE PAYABLE - OTHER	12 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]
NOTE PAYABLE - OTHER	Note 11 – NOTE PAYABLE –OTHER
	On November 1, 2013, the Company issued a $30,000 promissory note to a vendor who provide monitoring services to the Company. The note is non-interest bearing and due on June 1, 2014. The note will be paid in six installment payments with $5,000 due on the first day of each month from January to June 2014. Based on the note, all subscribers monitoring agreements owned or newly originated by the Company must be monitored by the note holder until the terms of the agreement are satisfied. This note is guaranteed by the CEO of the Company. As of June 30, 2014, unpaid balance was $5,000 which was paid in July 2014.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 12 - RELATED PARTY TRANSACTIONS
	During the fiscal years ended June 30, 2013, the Company issued various convertible notes to certain shareholders. (See Note 7)
	Interest expenses to shareholder loans were $31,909 and $72,349 for the years ended June 30, 2014 and 2013, respectively, zero amount was paid during the years ended June 30, 2014 and 2013, respectively.
	On June 14, 2013, the Company issued a $29,000 promissory note to a family member of the Company’s CEO. The note is non-interest bearing and due on June 13, 2014. The note was converted to 36,250 shares of common stock on February 5, 2014.
	On February 5, 2014 the Company issued 50,000 shares of common stock to a shareholder as compensation for consulting services provided to the Company. Those shares were valued at the quoted market price for total $38,500 and recorded as expense.
	On December 10, 2013, the Company issued 1,493,669 shares of common stock to management team per Global Settlement Agreement. (See Note 8)

INCOME_TAX

INCOME TAX	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 13 – INCOME TAX
	The reconciliation of income tax benefit at the U.S. statutory rate of 34% for the years ended June 30, 2014 and 2013 to the Company’s effective tax rate is as follows:
		Year ended June 30,
		2014			2013
	U.S. federal statutory rate		34	%		34	%
	State income tax, net of federal benefit		9.99	%		9.99	%
	Permeant difference – change in fair value of derivative instrument and non-cash interest expense		(296.14	%)		(57.41	%)
	Change in valuation allowance		252.15	%		13.42	%
	Income tax provision (benefit)		0	%		0	%
	The benefit for income tax is summarized as follows:
		Year ended June 30,
		2014			2013
	Federal:
	Current	$	—		$	—
	Deferred		(438,568	)		(330,858	)
	State and local:
	Current		—			—
	Deferred		(128,862	)		(97,214	)
	Change in valuation allowance		567,430			428,072
	Income tax provision (benefit)	$	—		$	—
	The tax effects of temporary differences that give rise to the Company’s net deferred tax liability as of June 30, 2014 and 2013 are as follows:
		Year ended June 30,
		2014			2013
	Net operating losses carried forward	$	4,784,732		$	4,217,302
	Less: valuation allowance		(4,784,732	)		(4,217,302	)
	Deferred tax assets	$	—		$	—
	As of June 30, 2014, the Company had approximately $ 11 million of federal and state net operating loss carryovers (“NOLs”) which begin to expire in 2028. Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.
	In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against the entire deferred tax asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be realized.
	The Company files U.S. federal and states of Pennsylvania tax returns that are subject to audit by tax authorities beginning with the year ended June 30, 2008.The Company’s policy is to classify assessments, if any, for tax and related interest and penalties as tax expense.

CONCENTRATION_AND_CREDIT_RISK

CONCENTRATION AND CREDIT RISK	12 Months Ended
	Jun. 30, 2014
Risks and Uncertainties [Abstract]
CONCENTRATION AND CREDIT RISK	NOTE 13 - CONCENTRATION AND CREDIT RISK
	Sales to one customer accounted for approximately 17% and 19% of the Company’s revenue for the year ended June 30, 2014 and 2013, respectively.
	The Company had only one supplier during the years ended June 30, 2014 and 2013, respectively.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 – SUBSEQUENT EVENT
	On August 21, 2014, the Company granted 5,000 shares of common stock to an individual as compensation for his services pursuant to a “Restricted Stock Grant Notice” between the Company and the consultant dated July 1, 2014.

RESTATEMENT_OF_CONSOLIDATED_BA

RESTATEMENT OF CONSOLIDATED BALANCE SHEETS	12 Months Ended
	Jun. 30, 2014
Notes to Financial Statements
RESTATEMENT OF CONSOLIDATED BALANCE SHEETS	NOTE 15 - RESTATEMENT OF CONSOLIDATED BALANCE SHEETS
	The management of the Company has concluded that we should restate our consolidated balance sheets as of June 30, 2014 and 2013. The conclusion was reached by management because they determined that the patent payable was improperly classified on balance sheets as of June 30, 2014 and 2013.
	The effect of the restatement on specific line items in the financial statements as of June 30, 2014 and 2013 is set forth in the table below:
	Consolidated Balance Sheet as of June 30, 2014
		Previously
		Reported		Adjustments			As Restated
	Patent payable	$	—	$	2,500,00		$	2,500,000
	Total current liabilities	$	703,401	$	2,500,000		$	3,203,401
	Patent payable	$	2,500,000	$	(2,500,000	)	$	—
	Total non-current liabilities	$	2,500,000	$	(2,500,000	)	$	—
	Consolidated Balance Sheet as of June 30, 2013
		Previously
		Reported		Adjustments			As Restated
	Patent payable	$	—	$	2,500,00		$	2,500,000
	Total current liabilities	$	3,253,570	$	2,500,000		$	5,753,570
	Patent payable	$	2,500,000	$	(2,500,000	)	$	—
	Total non-current liabilities	$	3,344,009	$	(2,500,000	)	$	844,009

SUMMARY_OF_ACCOUNTING_POLICIES1

SUMMARY OF ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation
	The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”).
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant inter-company transactions and balances among the Company and its subsidiary are eliminated upon consolidation.
	Certain amounts included in June 30, 2013 financial statements have been reclassified to conform to the June 30, 2014 financial statements presentation.
Reverse Split	Reverse Split
	On February 14, 2014, the company filed a Certificate of Change with the State of Nevada to effect a 1-for-800 reverse stock split on the issued and outstanding preferred and common stock. All relevant information relating to numbers of shares, warrants and per share information have been retrospectively adjusted to reflect the reverse stock split for all periods presented.
Use of Estimates	Use of Estimates
	The preparation of the financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include the collectability of accounts receivable, deferred taxes and related valuation allowances and value of derivative financial instruments. Certain of our estimates, including evaluating the collectability of accounts receivable, could be affected by external conditions, including those unique to our industry, and general economic conditions. It is possible that these external factors could have an effect on our estimates that could cause actual results to differ from our estimates. We re-evaluate all of our accounting estimates at least quarterly based on these conditions and record adjustments when necessary.
Cash	Cash
	The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash and cash equivalents.
Accounts receivable and allowance for doubtful accounts receivable	Accounts receivable and allowance for doubtful accounts receivable
	We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. We extend credit to our customers based on an evaluation of their financial condition and other factors. We generally do not require collateral or other security to support accounts receivable. We perform ongoing credit evaluations of our customers and maintain an allowance for potential bad debts if required.  We determine whether an allowance for doubtful accounts is required by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. In these cases, we use assumptions and judgment, based on the best available facts and circumstances, to record a specific allowance for those customers against amounts due to reduce the receivable to the amount expected to be collected. These specific allowances are re-evaluated and adjusted as additional information is received. The amounts calculated are analyzed to determine the total amount of the allowance. We may also record a general allowance as necessary.  Direct write-offs are taken in the period when we have exhausted our efforts to collect overdue and unpaid receivables or otherwise evaluate other circumstances that indicate that we should abandon such efforts.
Inventory	Inventory
	The Company values inventory, consisting of purchased products, at the lower of cost or market. Cost is determined on the first-in and first-out (“FIFO”) method. The Company regularly reviews its inventories on hand and, when necessary, records a provision for excess or obsolete inventories based primarily on current selling price and spot market prices. The Company determined that there was no inventory obsolescence as of June 30, 2014 and 2013.
Property and equipment	Property and equipment
	Property and equipment includes furniture and fixtures and office equipment which are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of furniture and fixtures and office equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over their estimated useful life of seven (7) and five (5) years, respectively. Upon sale or retirement of office equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in statements of operations.
Patent	Patent
	The Company has adopted the guidelines as set out in section 330-30-35-6 of the FASB Accounting Standards Codification (“ASC”) for patent costs. Under the requirements as set out, the Company capitalizes and amortizes patent costs associated with the licensed product the Company intends to sell pursuant to the Purchase Agreement and the Patent Assignment Agreements, entered into on July 10, 2008 and effective July 30, 2008, over their estimated useful life. From July 30, 2008 to March 31, 2011, the patent cost was amortized over the period of six years. The company changed the estimated useful life of patent from six years to twenty years. From April 1, 2011, the unamortized balance of patent costs will be amortized over the remaining period of useful life. The costs of defending and maintaining patents are expensed as incurred. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
Impairment of long-lived assets	Impairment of long-lived assets
	The Company follows section 360-10-05-4 of the FASB ASC for its long-lived assets. The Company’s reviews it long-lived assets, which include property and equipment, and patent, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
	The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future undiscounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated or amortized over the newly determined remaining estimated useful lives. The Company determined that there were no impairments of long-lived assets as of June 30, 2014 and 2013.
Convertible instruments and derivative financial instruments	Convertible instruments and derivative financial instruments
	The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with paragraph 810-10-05-4 of the FASB ASC and paragraph 815-40-25 of the FASB ASC. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the Statement of Operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.
	In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.
	On January 1, 2009, the Company adopted Section 815-40-15 of the FASB ASC (“Section 815-40-15”) to determine whether an instrument (or an embedded feature) is indexed to the Company’s own stock. Section 815-40-15 provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The adoption of Section 815-40-15 has affected the accounting for (i) certain freestanding warrants that contain exercise price adjustment features and (ii) convertible bonds issued by foreign subsidiaries with a strike price denominated in a foreign currency.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company follows paragraph 825-10-50-10 of the FASB ASC for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value pursuant to GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:
	Level 1   Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
	Level 2   Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
	Level 3   Pricing inputs that are generally observable inputs and not corroborated by market data.
	The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, inventory, prepaid expenses, accounts payable, deferred revenues and accrued liabilities, approximate their fair values because of the short maturity of these instruments. The Company’s convertible notes payable approximate the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at June 30, 2014 and 2013.
	The derivative liability which consists of embedded conversion feature and warrants issued in connection with our convertible debt, classified as a level 3 liability, are the only financial liability measured at fair value on a recurring basis. (See Note 10)
Income Taxes	Income Taxes
	The Company accounts for income taxes under the provisions of FASB ASC Topic 740, “Income Tax,” which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are recognized for the future tax consequence attributable to the difference between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are measured using the enacted tax rate expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company establishes a valuation when it is more likely than not that the assets will not be recovered.
	ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for any of the reporting periods presented.
Revenue Recognition	Revenue Recognition
	The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical or age-related conditions. The Company applies paragraph 605-10-S99-1 of the FASB ASC for revenue recognition. The Company will recognize revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement that the services have been rendered to the customer, the sales price is fixed or determinable, and collectability is reasonably assured.
	All revenues from subscription arrangements are recognized ratably over the term of such arrangements. The excess of amounts received over the income recognized is recorded as deferred revenue on the consolidated balance sheet.
Shipping and Handling Costs	Shipping and handling costs
	The Company accounts for shipping and handling fees in accordance with paragraph 605-45-45-19 of the FASB ASC. While amounts charged to customers for shipping products are included in revenues, the related costs are classified in cost of goods sold as incurred.
Stock-Based Compensation	Stock-based compensation
	We recognize compensation expense for stock-based compensation in accordance with ASC Topic 718. For employee stock-based awards, we calculate the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for unrestricted shares; the expense is recognized over the service period for awards expected to vest. For non-employee stock-based awards, we calculate the fair value of the award on the date of grant in the same manner as employee awards. However, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.
	The Black-Scholes option valuation model is used to estimate the fair value of the warrants or options granted. The model includes subjective input assumptions that can materially affect the fair value estimates. The model was developed for use in estimating the fair value of traded options or warrants. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the warrants or options granted.
Net Income per Common Share	Net loss per common share
	Net loss per common share is computed pursuant to section 260-10-45 of the FASB ASC. Basic net loss per common share is computed by taking net loss divided by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and convertible debt. These potential shares of common stock were not included as they were anti-dilutive.
Commitments and contingencies	Commitments and contingencies
	The Company follows subtopic 450-20 of the FASB ASC to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
Cash flows reporting	Cash flows reporting
	The Company adopted paragraph 230-10-45-24 of the FASB ASC for cash flows reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by paragraph 230-10-45-25 of the FASB ASC to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The Company reports the reporting currency equivalent of foreign currency cash flows, using the current exchange rate at the time of the cash flows and the effect of exchange rate changes on cash held in foreign currencies is reported as a separate item in the reconciliation of beginning and ending balances of cash and cash equivalents and separately provides information about investing and financing activities not resulting in cash receipts or payments in the period pursuant to paragraph 830-230-45-1 of the FASB Accounting Standards Codification.
Subsequent events	Subsequent events
	The Company follows the guidance in Section 855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company evaluates subsequent events through the date when the financial statements are issued. Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR.
Recently Accounting Pronouncements	Recently Accounting Pronouncements
	In April 2014, the FASB issued amendments to ASC Topic 205 “Presentation of Financial Statements” and ASC Topic 360 “Property, Plant and Equipment”. The amendments change the current requirements for reporting discontinued operations in Subtopic 205-20. It requires an entity to present, for each comparative period, the assets and liabilities of a disposal group that includes a discontinued operation separately in the asset and liability section, respectively, of the statement of financial position. This topic is effective for public entities for reporting periods beginning after December 15, 2014. An entity should not apply the amendments to a component classified as held for sale before the effective date even if the component of an entity is disposed of after the effective date. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued. The Company does not believe the adoption of the amendments to ASC 205 and ASC 360 will have a material effect on its consolidated financial statements.
	Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Jun. 30, 2014
Notes to Financial Statements
Patent, stated at cost, less accumulated amortization	Patent, stated at cost, less accumulated amortization consisted of the following:
		30-Jun-14		June30,2013
	Patent	$	2,500,000	$	2,500,000
	Less: accumulated amortization		-1,400,964		-1,322,462
		$	1,099,036	$	1,177,538

ACCRUED_EXPENSES_AND_OTHER_CUR1

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]
Accrued expenses and other current liabilities.	The following table presents accrued expenses and other current liabilities.
			30-Jun-14		30-Jun-13
	Accrued expenses	$	194,025	$	169,952
	Accrued interest		-		107,988
	Stock to be issued		-		54,400
	Advance from customer		-		35,458
	Total	$	194,025	$	367,798

CONVERTIBLE_NOTES_PAYABLE_Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	12 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]
Convertible promissory notes movement	The following table summarizes the convertible promissory notes movement of fiscal 2014 and 2013:
	Balance at June 30, 2012	$	347,610
	Convertible notes issued		58,000
	Convertible notes converted		-64,883
	Total		340,727
	Less: debt discount		-61,232
	Balance at June 30, 2013		279,495
	Less: current portion		-54,330
	Long-term portion		225,165
	Balance at June 30, 2013		340,727
	Convertible notes issued		-
	Convertible notes converted		-314,819
	Total		25,908
	Less: debt discount		-
	Balance at June 30, 2014		25,908

WARRANTS_Tables

WARRANTS (Tables)	12 Months Ended
	Jun. 30, 2014
Notes to Financial Statements
Movement of warrants	The following table summarizes the movement of warrants:
		Number of shares
		Prior to	After	Weighted
		Reverse	Reverse	average
		Stock Split	Stock Split	exercise price
	Outstanding at June 30, 2012	139,683,763	174,605	0.0002
	Granted	41,000,000	51,250	0.0014
	Exercised	1,181,707	1,477	0.0002
	Forgiven	179,502,056	224,378	0.0002
	Outstanding at June 30, 2013	-	-	-

DERIVATIVE_WARRANT_LIABILITY_A1

DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Tables)	12 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]
Fair value of outstanding warrants	Significant assumptions used in calculating fair value of outstanding warrants are as follows.
	Expected	Expected	Risk-free	Expected	Exercise	Underlying
	dividend	volatility	Rate of	term	price	Number of shares
			interest	(year)
	-	193.89% - 322.21%	0.07 %/ 1 year	As set forth by each promissory note agreement	$0.00	As set forth by each promissory note agreement
			0.35 %/ 2 years
			0.5 %/ 3 years
Recurring basis using significant unobservable inputs	The following table provides a summary of the changes in fair value of derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs during the year ended June 30, 2014 and 2013.
	Balance - July 1, 2012	8,043,577
	Issuances during the year	261,230
	Conversion and forgiveness during the year	-1,349,122
	changes in fair value included in earnings	-4,500,057
	Balance - June 30, 2013	2,455,628
	Issuances during the year	-
	Conversion during the year	-909,915
	changes in fair value included in earnings	-1,514,947
	Balance - June 30, 2014	30,766

INCOME_TAX_Tables

INCOME TAX (Tables)	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Reconciliation income tax benefit	The reconciliation of income tax benefit at the U.S. statutory rate of 34% for the years ended June 30, 2014 and 2013 to the Company’s effective tax rate is as follows:
		Year ended June30,
		2014		2013
	U.S. federal statutory rate	-34	%	-34	%
	State income tax, net of federal benefit	-9.99	%	-9.99	%
	Permeant difference – change in fair value of derivative instrument and non-cash interest expense	-296.14%		-296.14%
	Change in valuation allowance	252.15	%	252.15	%
	Income tax provision (benefit)	0	%	0	%
Benefit for income tax	The benefit for income tax is summarized as follows:
		Year ended June30,
		2014		2013
	Federal:
	Current	$	-	$	-
	Deferred		-438,568		-330,858
	State and local:
	Current		-		-
	Deferred		-128,862		-97,214
	Change in valuation allowance		567,430		428,072
	Income tax provision (benefit)	$	-	$	-
Tax effects of temporary net deferred tax liability	The tax effects of temporary differences that give rise to the Company’s net deferred tax liability as of June 30, 2014 and 2013 are as follows:
		Year ended June30,
		2014		2013
	Net operating losses carried forward	$	4,784,732	$	4,217,302
	Less: valuation allowance		-4,784,732		-4,217,302
	Deferred tax assets	$	-	$	-

RESTATEMENT_OF_CONSOLIDATED_BA1

RESTATEMENT OF CONSOLIDATED BALANCE SHEETS (Tables)	12 Months Ended
	Jun. 30, 2014
Notes to Financial Statements
Schedule of Restatement Balance Sheet	Consolidated Balance Sheet as of June 30, 2014
		Previously
		Reported		Adjustments			As Restated
	Patent payable	$	—	$	2,500,00		$	2,500,000
	Total current liabilities	$	703,401	$	2,500,000		$	3,203,401
	Patent payable	$	2,500,000	$	(2,500,000	)	$	—
	Total non-current liabilities	$	2,500,000	$	(2,500,000	)	$	—
	Consolidated Balance Sheet as of June 30, 2013
		Previously
		Reported		Adjustments			As Restated
	Patent payable	$	—	$	2,500,00		$	2,500,000
	Total current liabilities	$	3,253,570	$	2,500,000		$	5,753,570
	Patent payable	$	2,500,000	$	(2,500,000	)	$	—
	Total non-current liabilities	$	3,344,009	$	(2,500,000	)	$	844,009

SUMMARY_OF_ACCOUNTING_POLICIES2

SUMMARY OF ACCOUNTING POLICIES (Details Narrative) (Furniture and Fixtures [Member])	12 Months Ended
	Jun. 30, 2014
Minimum [Member]
Property and equipment estimated useful life	5 years
Maximum [Member]
Property and equipment estimated useful life	7 years

GOING_CONCERN_Details_Narrativ

GOING CONCERN (Details Narrative) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital deficit	$635,937
Stockholders' deficit	($2,036,440)	($5,338,066)	($10,247,747)

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Patent Details
Patent	$2,500,000	$2,500,000
Less: accumulated amortization	-1,400,964	-1,322,462
Intangible Assets, Net	$1,099,036	$1,177,538

INTANGIBLE_ASSETS_Details_Narr

INTANGIBLE ASSETS (Details Narrative) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Notes to Financial Statements
Obligated to pay the seller			$2,500,000
Amortization of patent aggregated	$78,503	$78,503

ACCRUED_EXPENSES_AND_OTHER_CUR2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Payables and Accruals [Abstract]
Accrued expenses	$194,025	$169,952
Accrued interest		107,988
Stock to be issued		54,400
Advance from customer		35,458
Total	$194,025	$367,798

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Debt Disclosure [Abstract]
Balance at June 30	$340,727	$347,610
Convertible notes issued		58,000
Convertible notes converted	-314,819	-64,883
Balance at June 30	25,908	340,727
Less: debt discount		-61,232
Balance at June 30	25,908	279,495
Less: current portion		-54,330
Long-term portion		$225,165

STOCKHOLDERS_EQUITY_Details_Na

STOCKHOLDERS EQUITY (Details Narrative) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Issuance of common stocks for cash, Amount	$76,900	$291,751
Investor [Member]
Issuance of common stocks for cash, Shares	123,014
Issuance of common stocks for cash, Amount	76,900
Liability for common stock	$54,400

WARRANTS_Details

WARRANTS (Details) (USD $)	12 Months Ended
	Jun. 30, 2013
Number of shares Prior to Reverse Stock Split
Outstanding at June 30	139,683,763
Granted	41,000,000
Exercised	1,181,707
Forgiven	179,502,056
Outstanding at June 30
Number of shares After Reverse Stock Split
Outstanding at June 30	174,605
Granted	51,250
Exercised	1,477
Forgiven	224,378
Outstanding at June 30
Weighted average exercise price
Outstanding at June 30	$0.00
Granted	$0.00
Exercised	$0.00
Forgiven	$0.00
Outstanding at June 30

WARRANTS_Details_Narrative

WARRANTS (Details Narrative) (USD $)	12 Months Ended
	Jun. 30, 2013
Notes to Financial Statements
Purchase forgive warrants	224,378
Derivative liability	$403,417

DERIVATIVE_LIABILITY_AND_FAIR_

DERIVATIVE LIABILITY AND FAIR VALUE (Details) (USD $)	12 Months Ended
	Jun. 30, 2014
Fair Value Assumptions, Expected Dividend
Fair Value Assumptions, Exercise Price	$0.00
Fair Value Assumptions Underlying Number Of Shares	As set forth by each promissory note agreement
Fair Value Assumptions, Expected Term (years)	As set forth by each promissory note agreement
Warrant One [Member]
Fair Value Assumptions, Risk-free rate of interest	0.07%
Fair Value Assumptions, Expected Term	1 year
Warrant Two [Member]
Fair Value Assumptions, Risk-free rate of interest	0.35%
Fair Value Assumptions, Expected Term	2 years
Warrant Three [Member]
Fair Value Assumptions, Risk-free rate of interest	0.50%
Fair Value Assumptions, Expected Term	3 years
Maximum [Member]
Fair Value Assumptions, Expected Volatility	322.21%
Minimum [Member]
Fair Value Assumptions, Expected Volatility	193.89%

DERIVATIVE_WARRANT_LIABILITY_A2

DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Details 1) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Fair Value Disclosures [Abstract]
Balance - July 1, 2012	$2,455,628	$8,043,577
Issuances during the year		261,230
Conversion and forgiveness during the year	-909,915	-1,349,122
changes in fair value included in earnings	-1,514,947	-4,500,057
Balance - June 30, 2013	$30,766	$2,455,628

DERIVATIVE_WARRANT_LIABILITY_A3

DERIVATIVE WARRANT LIABILITY AND FAIR VALUE (Details Narrative) (USD $)	12 Months Ended
	Jun. 30, 2013
Fair Value Disclosures [Abstract]
Interest expense relating to the excess fair value	$261,230

NOTE_PAYABLE_OTHER_Details_Nar

NOTE PAYABLE - OTHER (Details Narrative) (USD $)	Jun. 30, 2014
Debt Disclosure [Abstract]
Unpaid balance note payable	$5,000

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Related Party Transactions [Abstract]
Interest expenses to shareholder loans	$31,909	$72,349

INCOME_TAX_Details

INCOME TAX (Details)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]
U.S. federal statutory rate	-34.00%	-34.00%
State income tax, net of federal benefit	-9.99%	-9.99%
Permeant difference - change in fair value of derivative instrument and non-cash interest expense	-296.14%	-296.14%
Change in valuation allowance	252.15%	252.15%
Income tax provision (benefit)	0.00%	0.00%

INCOME_TAX_Details_1

INCOME TAX (Details 1) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Federal:
Current
Deferred	-438,568	-330,858
State and local:
Current
Deferred	-128,862	-97,214
Change in valuation allowance	567,430	428,072
Income tax provision (benefit)

INCOME_TAX_Details_2

INCOME TAX (Details 2) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Net operating losses carried forward	$4,784,732	$4,217,302
Less: valuation allowance	-4,784,732	-4,217,302
Deferred tax assets

INCOME_TAX_Details_Narrative

INCOME TAX (Details Narrative) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]
U.S. statutory rate	34.00%	34.00%
Federal and state net operating loss	$11,000,000

CONCENTRATION_AND_CREDIT_RISK_

CONCENTRATION AND CREDIT RISK (Details Narrative)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Risks and Uncertainties [Abstract]
Customer sales revenue	17.00%	19.00%

RESTATEMENT_OF_CONSOLIDATED_BA2

RESTATEMENT OF CONSOLIDATED BALANCE SHEETS (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Total current liabilities	$703,401	$3,253,570
Patent payable	2,500,000	2,500,000
Total non-current liabilities	2,500,000	3,344,009
Previously Reported [Member]
Patent payable
Total current liabilities	703,401	3,253,570
Patent payable	2,500,000	2,500,000
Total non-current liabilities	2,500,000	3,344,009
Adjustments [Member]
Patent payable	250,000	250,000
Total current liabilities	2,500,000	2,500,000
Patent payable	-2,500,000	-2,500,000
Total non-current liabilities	-2,500,000	-2,500,000
Restatement Adjustment [Member]
Patent payable	2,500,000	2,500,000
Total current liabilities	3,203,401	5,753,570
Patent payable
Total non-current liabilities		$844,009